The Potential Relationship Between Cardiovascular Diseases and Monkeypox

Area of Science:

• Infectious Diseases
• Cardiology
• Public Health

Background:

• Mpox virus (mpox) emerged globally in May 2022, distinct from the COVID-19 pandemic.
• The 2022 outbreak involved Clade II mpox, not Clade I, affecting over 115 countries with nearly 90,500 cases by September 2023.
• Emerging evidence links mpox to cardiovascular complications, including myocarditis and pericarditis.

Purpose of the Study:

• To provide a clinical cardiologist's perspective on mpox.
• To review the epidemiological characteristics of mpox.
• To discuss primary mpox treatments relevant to cardiovascular physicians.

Main Methods:

• Literature review focusing on mpox epidemiology and clinical manifestations.
• Analysis of global mpox case data and outbreak characteristics.
• Synthesis of current knowledge on mpox treatments and cardiovascular risks.

Main Results:

• The 2022 mpox outbreak was identified as Clade II.
• Mpox cases have surpassed 90,439 globally since May 2022.
• Cardiovascular complications are a significant concern in mpox patients.

Conclusions:

• Cardiovascular physicians need to be aware of mpox and its potential cardiac sequelae.
• Understanding mpox epidemiology and treatment is crucial for managing affected patients.
• Further research is needed to fully elucidate the cardiovascular impact of mpox.